How NanoACi differs from ACI, MACI and symptom injections

Three categories, one decision

When a scan confirms cartilage damage, the question that follows is almost always the same: is there anything that can be done without a major operation? Answering it well means understanding that the treatments on offer belong to three quite different categories — different not just in how they are delivered, but in what they are trying to achieve.

The first category is surgical and cell-based. ACI (Autologous Chondrocyte Implantation) and MACI (Matrix-induced Autologous Chondrocyte Implantation) both aim to regenerate cartilage through two staged hospital procedures — the first to harvest cells, the second to implant them after a laboratory culture period of several weeks.

The second is palliative injection: hyaluronic acid, corticosteroids, and synthetic hydrogels such as Arthrosamid. These are designed to ease symptoms — lubricating, cushioning, or dampening inflammation — without attempting to rebuild the tissue itself.

The third is NanoACi™ — Professor Paul Lee's surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique. It aims at tissue regeneration, like ACI and MACI, but reaches that goal through an injection rather than an operating theatre. This article maps the structural and conceptual differences between all three; component evidence and combined-protocol outcomes are addressed separately, and no outcome ranking between approaches is made here.

What ACI and MACI actually require

Both procedures share the same underlying architecture, but differ in how cells are ultimately delivered.

In ACI, a first arthroscopic operation takes a small cartilage biopsy from a low-load area of the joint. Those cells — chondrocytes — travel to an external laboratory, where they are expanded in culture over several weeks. A second procedure then returns the patient to theatre: the expanded cell suspension is injected beneath a periosteal flap, a thin membrane harvested from the patient's shin, which holds the repair in place.

MACI refines the delivery step without changing the staging. Harvested chondrocytes are cultured in the same way, but instead of a free suspension they are pre-seeded onto a flat collagen membrane before the second operation. Implantation remains surgical; the membrane is fixed directly over the defect, removing the need for the periosteal flap.

Both pathways therefore involve two separate operations divided by a laboratory culture interval, two episodes of anaesthesia, and a structured rehabilitation programme after surgical implantation. The branded MACI product that served European markets is no longer available in the UK following the closure of its manufacturing site. STACi — a single-stage surgical technique that brings cell preparation and implantation into one operative procedure, without the external culture interval — has emerged as one current evolution within this surgical space.

With a substantial body of long-term data behind them, ACI and MACI remain the established reference standard for cell-based cartilage repair.

What symptom-relief injections are designed to do

Pain relief and cartilage repair are not the same goal, and most injection treatments are designed explicitly for the first.

Hyaluronic acid works as a temporary lubricant. Injected into the joint space, it supplements the viscous fluid that reduces friction between surfaces. The joint clears it within weeks, so any benefit is short-lived and does not alter the underlying tissue. Corticosteroids work differently — they dampen the inflammatory signalling that drives pain and swelling — but again the target is the biological environment around the cartilage, not the cartilage itself. Hydrogels such as Arthrosamid take a third approach: a synthetic gel cushions the joint mechanically and may remain in place longer, but it is not a biological material the body can integrate or remodel into cartilage-like tissue.

Therapeutic intent is what separates this category from cell-based approaches. All three injection types are designed to make the joint feel better; none is designed to rebuild structural cartilage.

This distinction matters because NanoACi is also needle-delivered — a shared delivery route that is the most frequent source of confusion between categories, and one the next section addresses directly.

NanoACi's three-part architecture

The architecture of NanoACi rests on three biological roles, each handled by a specific component and all combined within a single planned sitting.

The seed is mechanically prepared autologous auricular cartilage micrografts — cells sourced not from the joint being treated, but from the outer ear. Three 2.5 mm punch biopsies are taken from behind the ear under local anaesthetic; the donor site heals within a week and the mark sits concealed within the ear fold. The ear's perichondrium — the layer surrounding its elastic cartilage — is described as holding more regenerative potential gram-for-gram than articular cartilage inside a joint, and harvesting there leaves the surface being repaired entirely undisturbed.

The scaffold is ChondroFiller, a cell-free native type I collagen matrix. Its role is structural: to provide a framework that arriving cells can populate and, over time, remodel into cartilage-like tissue.

The signal is ArthroZheal PRF — autologous platelet-rich fibrin prepared from the patient's own blood in a sealed automated system — intended to sustain growth-factor signalling at the repair site.

Sampling, preparation, combination and image-guided delivery all take place at point of care in one planned procedure, with no external laboratory cell-culture stage and no enzyme digestion in the described preparation. Needle delivery is the access route, not the sum total of what the technique involves; specialist imaging review, case selection, tissue sequencing and follow-up are integral to the planned procedure as Professor Paul Lee designed it.

Evidence for each individual component exists separately. The exact three-part combined protocol is being evaluated prospectively through the NanoACi 100 programme, and randomised trial data for the combination as a whole are not yet available.

Where the conceptual differences lie

Placing all three categories side by side across four axes produces a pattern that is harder to see when each approach is described in isolation.

Delivery route. ACI and MACI both require access through an operative theatre — arthroscopic or open. Palliative injections and NanoACi share the needle route, which is the primary source of patient confusion between them: the mechanism of access looks the same; what is being delivered, and why, is not.

Session count. ACI and MACI each require at least two separate procedures with a laboratory culture interval between them. Palliative injections and NanoACi are both completed in a single sitting — again a surface similarity that masks a difference in purpose.

Cell source. ACI and MACI biopsy from the articular surface under treatment. NanoACi sources micrografts from the ear's perichondrium, leaving the joint surface undisturbed. Palliative injections involve no cell harvest of any kind.

Therapeutic intent. ACI, MACI and NanoACi are each designed with a chondrogenic goal. Palliative injections are designed for symptom management. On this axis, NanoACi aligns with the surgical benchmarks — not with the injection category it superficially resembles on the delivery-route axis.

The pattern that emerges from reading across all four axes is the useful finding: NanoACi shares its delivery route and single-session format with palliative injections, but shares its chondrogenic intent and cell-based rationale with ACI and MACI. In structural terms it occupies an intersection — a surgical-science approach in a needle format — rather than belonging cleanly to either the surgical or the palliative column.

These remain architectural distinctions, not outcome claims. Whether a needle-delivered, point-of-care, single-stage protocol can achieve chondrogenic results comparable to laboratory-expanded cell implantation is the prospective question NanoACi 100 is built to answer.

Evidence, uncertainty and how suitability is assessed

Component evidence and combined-protocol evidence are separate things, and conflating them would misrepresent where NanoACi currently stands.

Each of the three components carries its own research foundation: ear-cartilage micrografts are supported by neural-crest biology and clinical studies reporting sustained reductions in pain and improved function; the ChondroFiller collagen scaffold has trial data comparing it with microfracture and more than a decade of multi-joint clinical use; autologous PRF has established biological credentials as a sustained growth-factor source. What the evidence base does not yet include is a randomised controlled trial of the exact combined three-part protocol. That gap is not concealed — it is the reason NanoACi 100 exists. The programme is gathering prospective outcomes data for the combined technique specifically, and its findings will either strengthen or qualify the rationale built from component evidence alone.

The open question NanoACi 100 is built to answer is the same one running through this article's four-axes framework: can point-of-care, single-stage preparation achieve chondrogenic results comparable to laboratory-expanded cell implantation? On the delivery-route and session-count axes, NanoACi is structurally simpler than ACI or MACI. On the therapeutic-intent axis, it makes the same claim. Whether the biology supports that claim at an equivalent level of outcomes is what prospective data will address.

When a specialist assesses a patient — reviewing alignment, joint stability, symptom history, the pattern of cartilage loss, and treatment goals — the three-category taxonomy this article describes becomes a practical clinical decision rather than a conceptual one.